BSE · 537536
Denis Chem Lab Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹176 Cr with net profit ₹8 Cr — a 4.6% net margin, versus 6.59% the period before.
Shareholding
As of 2026-06-30
- Promoter38.98%
- Public61.01%
- FII0.01%
6,811 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.84× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #72 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Denis Chem Lab Ltd.(this company) | ₹97 Cr | 11.5 | 1.06 | 9.18% | 4.63% |
AI analysis
AI-generated · google/gemini-2.5-flashDenis Chem Lab Ltd. is listed on the Indian markets with a market capitalization of Rs 97 Cr. The company reported a revenue of Rs 175.67 Cr and a profit margin of 462.8%. Its earnings per share (EPS) stood at Rs 6.06. The stock's 52-week high was Rs 103 and its 52-week low was Rs 56.1.
Positives
- +The debt-to-equity ratio is low at 0.01, indicating minimal reliance on borrowed funds.
- +The profit margin is high at 462.8%.
- +Return on capital employed (ROCE) is 13.14%, indicating efficient use of capital.
- +No promoter pledges are reported as of Mar 2026.
Negatives
- −Revenue growth information is not available.
- −Quarterly EPS data is not provided in any of the disclosed quarterly results.
- −The promoter holding has decreased from 38.9808% to an unspecified lower figure since the last reported period.
Financial Performance
Denis Chem Lab Ltd. reported a revenue of Rs 175.67 Cr for the latest financial year (Mar 2025). Net profit for the same period was Rs 8.0758 Cr. Previous annual revenues were Rs 169.2097 Cr (Mar 2024), Rs 161.4412 Cr (Mar 2023), Rs 137.6024 Cr (Mar 2022), and Rs 109.6627 Cr (Mar 2021). Quarterly revenues have varied, with Rs 46.75 Cr in Mar 2026 and Rs 45.52 Cr in Dec 2025.
Profitability & Returns
The company's profit margin is reported at 462.8%. Return on equity (ROE) for the latest period is 9.18%, while return on capital employed (ROCE) is 13.14%. Earnings per share (EPS) for the latest full year was Rs 5.82, showing fluctuations from previous years such as Rs 8.04 (Mar 2024) and Rs 5.66 (Mar 2023).
Balance Sheet
Denis Chem Lab Ltd. has a debt-to-equity ratio of 0.01. The book value per share is Rs 65.99. Detailed breakdown of assets and liabilities is not available in the provided data, but the low debt-to-equity ratio indicates minimal leverage.
Ownership & Pledges
As of Mar 2026, promoter holding in Denis Chem Lab Ltd. is 38.9808%. Public shareholding stands at 61.012%. There were no promoter pledges reported for Fiscals 2016-2018 or Mar 2026.
Regulatory & Surveillance
No information regarding surveillance measures has been provided in the data. The number of shareholders reached 6927 by Mar 2026, increasing from 2450 in Mar 2017.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.